Compare ARLO & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARLO | AMLX |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2018 | 2021 |
| Metric | ARLO | AMLX |
|---|---|---|
| Price | $13.84 | $13.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $24.00 | $19.56 |
| AVG Volume (30 Days) | ★ 1.6M | 808.9K |
| Earning Date | 05-29-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 145.16 | 65.46 |
| EPS | ★ 0.14 | N/A |
| Revenue | N/A | ★ $380,786,000.00 |
| Revenue This Year | $8.88 | N/A |
| Revenue Next Year | $9.23 | N/A |
| P/E Ratio | $98.93 | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $7.85 | $3.11 |
| 52 Week High | $19.94 | $17.49 |
| Indicator | ARLO | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 55.10 | 46.18 |
| Support Level | $13.09 | $13.61 |
| Resistance Level | $14.34 | $15.27 |
| Average True Range (ATR) | 0.67 | 0.89 |
| MACD | 0.23 | -0.10 |
| Stochastic Oscillator | 50.39 | 11.80 |
Arlo Technologies Inc is engaged in the provision of security and video monitoring solutions for homes and businesses. It combines a cloud infrastructure and mobile app with various smart connected devices to provide users with visibility, insight, and a means to help protect and connect in real-time with the people and things from any location with a Wi-Fi or a cellular connection. The company offers subscription services such as Arlo Secure, Arlo Total Security, and Arlo Safe, and several categories of smart security devices, including smart Wi-Fi and LTE-enabled cameras, video doorbells, floodlight cameras, and home security systems. Geographically, the company generates a majority of its revenue from the United States, followed by Spain, Sweden, and other countries.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.